Last reviewed · How we verify
NCT02033096
Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
trial testing Stannsoporfin in Jaundice in 42 participants. Completed in 9 November 2015.
23 June 2015
Quick facts
| Lead sponsor | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 42 |
| Start date | 20 October 2008 |
| Primary completion | 23 June 2015 |
| Estimated completion | 9 November 2015 |
Drugs / interventions tested
- Stannsoporfin — full drug profile →
- Placebo Control
- Phototherapy (as needed)
Conditions studied
- Jaundice — all drugs for Jaundice →
- Neonatal Hyperbilirubinemia — all drugs for Neonatal Hyperbilirubinemia →
Sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company — full company profile →
Who can join
Adults 30 Days to 4, any sex, with Jaundice or Neonatal Hyperbilirubinemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational follow-up of participants from earlier interventional trial 64,185-202 (NCT00850993). No interventions were administered during this follow-up study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02033096
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stannsoporfin
Trials testing the same drug.
- NCT02000830 — Follow up Study of Patients Having Participated in Clinical Trial 64,185-204 · completed
- NCT01887327 — Stannsoporfin With Light Therapy for Newborn Babies With Jaundice · Phase 2 · completed
Other recruiting trials for Jaundice
Currently open trials in the same condition.
- NCT06421844 — A Prospective Study: Smart Phone Application for Measure Serum Bilirubin Through Sclera Images · recruiting
- NCT06173947 — SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury · recruiting
Other InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company trials
Trials by the same sponsor.
- NCT02000830 — Follow up Study of Patients Having Participated in Clinical Trial 64,185-204 · completed
- NCT01887327 — Stannsoporfin With Light Therapy for Newborn Babies With Jaundice · Phase 2 · completed
- NCT00076960 — Compassionate Use of Stanate (TM) [Stannsoporfin] · no longer available
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02033096 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
- Last refreshed: 15 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02033096.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing